Welcome to LookChem.com Sign In|Join Free

CAS

  • or

466-97-7

Post Buying Request

466-97-7 Suppliers

Recommended suppliersmore

This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

466-97-7 Usage

Description

Normorphine, also known as a metabolite of morphine, is a controlled substance derived from the opium plant. It is a crystalline solid that serves as a primary urinary metabolite of the opiate analgesic morphine. Normorphine is used in various applications such as pain prescription monitoring, urine drug testing, clinical toxicology, and forensic analysis.

Uses

Used in Pain Management:
Normorphine is used as an analgesic (narcotic) for the management of acute and chronic severe pain. It is a metabolite of morphine, which is known under trade names such as MS Contin, Kadian, Oramorph, and Roxanol. The analgesic properties of normorphine make it a valuable component in the treatment of severe pain conditions.
Used in Clinical Toxicology:
Normorphine is used as a reference solution in clinical toxicology for LC/MS or GC/MS applications. This helps in the identification and quantification of the substance in biological samples, which is crucial for understanding the effects of the drug and its potential toxicity.
Used in Forensic Analysis:
In forensic analysis, normorphine is used to detect and analyze the presence of the substance in biological samples. This is important for cases involving drug-related incidents or criminal investigations where the presence of controlled substances like normorphine is relevant.
Used in Urine Drug Testing:
Normorphine is utilized in urine drug testing to monitor the use of opiate analgesics like morphine. This helps in ensuring compliance with prescribed medications and detecting potential cases of drug abuse or addiction.
Used in Pain Prescription Monitoring:
The presence of normorphine in a patient's urine can indicate the use of morphine or other related opiate analgesics. This information is valuable for healthcare professionals in monitoring the effectiveness of pain management treatments and making necessary adjustments to the prescribed medication regimen.

Check Digit Verification of cas no

The CAS Registry Mumber 466-97-7 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,6 and 6 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 466-97:
(5*4)+(4*6)+(3*6)+(2*9)+(1*7)=87
87 % 10 = 7
So 466-97-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H17NO3/c18-11-3-1-8-7-10-9-2-4-12(19)15-16(9,5-6-17-10)13(8)14(11)20-15/h1-4,9-10,12,15,17-19H,5-7H2/t9-,10+,12-,15-,16-/m0/s1

466-97-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name NORMORPHINE

1.2 Other means of identification

Product number -
Other names N-Desmethylmorphine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:466-97-7 SDS

466-97-7Relevant articles and documents

Synthesis of Potential Haptens with Morphine Skeleton and Determination of Protonation Constants

K?teles, István,Mazák, Károly,Tóth, Gerg?,T?z, Boglárka,Hosztafi, Sándor

, (2020/09/17)

Vaccination could be a promising alternative warfare against drug addiction and abuse. For this purpose, so-called haptens can be used. These molecules alone do not induce the activation of the immune system, this occurs only when they are attached to an immunogenic carrier protein. Hence obtaining a free amino or carboxylic group during the structural transformation is an important part of the synthesis. Namely, these groups can be used to form the requisite peptide bond between the hapten and the carrier protein. Focusing on this basic principle, six nor-morphine compounds were treated with ethyl acrylate and ethyl bromoacetate, while the prepared esters were hydrolyzed to obtain the N-carboxymethyl- and N-carboxyethyl-normorphine derivatives which are considered as potential haptens. The next step was the coupling phase with glycine ethyl ester, but the reactions did not work or the work-up process was not accomplishable. As an alternative route, the normorphine-compounds were N-alkylated with N-(chloroacetyl)glycine ethyl ester. These products were hydrolyzed in alkaline media and after the work-up process all of the derivatives contained the free carboxylic group of the glycine side chain. The acid-base properties of these molecules are characterized in detail. In the N-carboxyalkyl derivatives, the basicity of the amino and phenolate site is within an order of magnitude. In the glycine derivatives the basicity of the amino group is significantly decreased compared to the parent compounds (i.e., morphine, oxymorphone) because of the electron withdrawing amide group. The protonation state of the carboxylate group significantly influences the basicity of the amino group. All of the glycine ester and the glycine carboxylic acid derivatives are currently under biological tests.

N-Demethylation of N-methyl alkaloids with ferrocene

Kok, Gaik B.,Scammells, Peter J.

supporting information; experimental part, p. 4499 - 4502 (2010/09/15)

Under Polonovski-type conditions, ferrocene has been found to be a convenient and efficient catalyst for the N-demethylation of a number of N-methyl alkaloids such as opiates and tropanes. By judicious choice of solvent, good yields have been obtained for dextromethorphan, codeine methyl ether, and thebaine. The current methodology is also successful for the N-demethylation of morphine, oripavine, and tropane alkaloids, producing the corresponding N-nor compounds in reasonable yields. Key pharmaceutical intermediates such oxycodone and oxymorphone are also readily N-demethylated using this approach.

Therapeutic compounds

-

Page/Page column 13, (2008/06/13)

This invention relates to novel structural analogues and derivatives of compounds with general analgesic or related pharmacological activity. In particular the invention relates to derivatives of opioid compounds, particularly morphine and related compounds, in which an opioid compound is linked via the nitrogen at position 17 to a spacer group, which in turn is linked to a charged group, or a pharmaceutically acceptable salt thereof. In particularly preferred embodiments the opioid compound is morphine, codeine, or buprenorphine.